PDCD1 and metastatic melanoma: In a mouse model of metastatic melanoma, the combination of anti-CSFR1 antibodies and anti-PD-1 induced complete tumor regression, suggesting that T cell-derived colony-stimulating factor-1 (CSF1) enhances melanoma resistance to PD-1 blockade therapy[34].